Gerd Munzert

3.8k total citations · 2 hit papers
63 papers, 3.1k citations indexed

About

Gerd Munzert is a scholar working on Oncology, Cell Biology and Molecular Biology. According to data from OpenAlex, Gerd Munzert has authored 63 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 24 papers in Cell Biology and 20 papers in Molecular Biology. Recurrent topics in Gerd Munzert's work include Microtubule and mitosis dynamics (21 papers), Multiple Myeloma Research and Treatments (13 papers) and Cancer Genomics and Diagnostics (13 papers). Gerd Munzert is often cited by papers focused on Microtubule and mitosis dynamics (21 papers), Multiple Myeloma Research and Treatments (13 papers) and Cancer Genomics and Diagnostics (13 papers). Gerd Munzert collaborates with scholars based in Germany, United States and Austria. Gerd Munzert's co-authors include Takao Tashiro, Tadataka Yamada, John DelValle, Ira Gantz, Y Konda, Hiroto Miwa, Yoshimasa Shimoto, Stanley J. Watson, Holger Fritsch and G. Stehle and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Gerd Munzert

63 papers receiving 3.1k citations

Hit Papers

Molecular cloning of a novel melanocortin receptor. 1993 2026 2004 2015 1993 2020 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Molecular cloning of a novel melanocortin receptor.
    1993 594 citations Ira Gantz, Takao Tashiro et al. profile →
  2. Anti–B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma
    2020 233 citations Gerd Munzert et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gerd Munzert Germany 28 1.4k 1.1k 939 537 514 63 3.1k
Bart Vanhaesebroeck United Kingdom 16 2.7k 1.9× 682 0.6× 588 0.6× 226 0.4× 129 0.3× 17 3.8k
Ulla Engström Sweden 33 2.9k 2.0× 656 0.6× 690 0.7× 73 0.1× 53 0.1× 48 4.1k
Florian Bassermann Germany 26 1.7k 1.2× 789 0.7× 432 0.5× 319 0.6× 335 0.7× 105 2.9k
Christian Wallasch Germany 11 2.3k 1.6× 1.1k 1.0× 340 0.4× 169 0.3× 33 0.1× 14 3.5k
Emmanuel Normant United States 22 1.3k 0.9× 370 0.3× 417 0.4× 234 0.4× 85 0.2× 50 2.0k
Iris Alroy Israel 19 2.2k 1.5× 1.7k 1.6× 528 0.6× 66 0.1× 29 0.1× 27 3.8k
Elizabeth J. Quackenbush United States 25 2.1k 1.4× 857 0.8× 419 0.4× 387 0.7× 47 0.1× 45 3.8k
Jean Paul ten Klooster Netherlands 23 2.7k 1.9× 472 0.4× 1.7k 1.8× 132 0.2× 26 0.1× 32 4.0k
Maria Rozakis-Adcock Canada 22 2.2k 1.6× 605 0.6× 663 0.7× 118 0.2× 37 0.1× 23 3.0k
Brian Duckworth United States 12 3.4k 2.4× 914 0.9× 1.2k 1.2× 347 0.6× 23 0.0× 15 4.9k

Countries citing papers authored by Gerd Munzert

Since Specialization
Citations

This map shows the geographic impact of Gerd Munzert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerd Munzert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerd Munzert more than expected).

Fields of papers citing papers by Gerd Munzert

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerd Munzert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerd Munzert. The network helps show where Gerd Munzert may publish in the future.

Co-authorship network of co-authors of Gerd Munzert

This figure shows the co-authorship network connecting the top 25 collaborators of Gerd Munzert. A scholar is included among the top collaborators of Gerd Munzert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gerd Munzert. Gerd Munzert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Awad, Mark M., Leena Gandhi, Joe Stephenson, et al.. (2016). An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC). Lung Cancer. 104. 126–130. 47 indexed citations
2.
Awada, Ahmad, Herlinde Dumez, Philippe Aftimos, et al.. (2015). Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity. Investigational New Drugs. 33(3). 611–620. 20 indexed citations
3.
4.
Vose, Julie M., Jonathan W. Friedberg, Edmund K. Waller, et al.. (2012). The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation study. Leukemia & lymphoma. 54(4). 708–713. 25 indexed citations
5.
Frost, Annette, K. Mross, Simone Steinbild, et al.. (2012). Phase I Study of the Plk1 Inhibitor BI 2536 Administered Intravenously on Three Consecutive Days in Advanced Solid Tumours. Current Oncology. 19(1). 28–35. 62 indexed citations
6.
Staab, Alexander, et al.. (2011). Comparison of different semi-mechanistic models for chemotherapy-related neutropenia: application to BI 2536 a Plk-1 inhibitor. Cancer Chemotherapy and Pharmacology. 68(6). 1517–1527. 11 indexed citations
7.
Schöffski, Patrick, Ahmad Awada, Herlinde Dumez, et al.. (2011). A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. European Journal of Cancer. 48(2). 179–186. 132 indexed citations
8.
Staab, Alexander, et al.. (2010). Prediction of Neutropenia-Related Effects of a New Combination Therapy With the Anticancer Drugs BI 2536 (a Plk1 Inhibitor) and Pemetrexed. Clinical Pharmacology & Therapeutics. 88(5). 660–667. 17 indexed citations
9.
Staab, Alexander, Christiane Tillmann, Dirk Trommeshauser, et al.. (2010). Semi-mechanistic population pharmacokinetic/pharmacodynamic model for neutropenia following therapy with the Plk-1 inhibitor BI 2536 and its application in clinical development. Cancer Chemotherapy and Pharmacology. 66(4). 785–795. 20 indexed citations
10.
11.
12.
Gandhi, Leena, Quincy S. Chu, John Stephenson, et al.. (2009). An open label phase II trial of the Plk1 inhibitor BI 2536, in patients with sensitive relapse small cell lung cancer (SCLC). Journal of Clinical Oncology. 27(15_suppl). 8108–8108. 14 indexed citations
13.
Baum, Anke, Pilar Garin‐Chesa, Ulrich Gürtler, Gerd Munzert, & Dorothea Rudolph. (2007). PD2-1-1: Efficacy of BI 2536, a potent and selective inhibitor of the mitotic kinase Plk1, in models of human non-small cell lung carcinoma. Journal of Thoracic Oncology. 2(8). S435–S436. 4 indexed citations
14.
15.
Munzert, Gerd, et al.. (2004). Constitutive NF-κB/Rel Activation in Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL). Leukemia & lymphoma. 45(6). 1181–1184. 29 indexed citations
16.
Shen, Changxian, Holger Schirrmeister, Alexandra Schmid‐Kotsas, et al.. (2002). Liposomal Delivery of Antisense Oligonucleotides for Efficient Downregulation of Bcl-2 and Induction of Apoptosis. Cancer Biotherapy and Radiopharmaceuticals. 17(3). 281–289. 8 indexed citations
17.
Munzert, Gerd, et al.. (2000). Normal Structure of NFKB 2, C-REL and BCL-3 Gene Loci in Lymphoproliferative and Myeloproliferative Disorders. Leukemia & lymphoma. 38(3-4). 395–400. 9 indexed citations
18.
Bai, Ren, Thomas Jähn, Gerd Munzert, et al.. (1998). The SH2-containing adapter protein GRB10 interacts with BCR-ABL. Oncogene. 17(8). 941–948. 46 indexed citations
19.
Munzert, Gerd, et al.. (1997). Concomitant manifestation of systemic lupus erythematosus and low-grade non-Hodgkin’s lymphoma. Leukemia. 11(8). 1324–1328. 16 indexed citations
20.
Gantz, Ira, Gerd Munzert, Takao Tashiro, et al.. (1991). Molecular cloning of the human histamine H2 receptor. Biochemical and Biophysical Research Communications. 178(3). 1386–1392. 151 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bart Vanhaesebroeck Breakdown of academic impact, for papers by Ulla Engström Breakdown of academic impact, for papers by Florian Bassermann Breakdown of academic impact, for papers by Christian Wallasch Breakdown of academic impact, for papers by Emmanuel Normant Breakdown of academic impact, for papers by Iris Alroy Breakdown of academic impact, for papers by Elizabeth J. Quackenbush Breakdown of academic impact, for papers by Jean Paul ten Klooster Breakdown of academic impact, for papers by Maria Rozakis-Adcock Breakdown of academic impact, for papers by Brian Duckworth
Rankless by CCL
2026